D2S Pharma
ActiveD2S Pharma has been active since 2014 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €425k and a net result of €38k. Equity is growing by ~14.3% per year across the filed fiscal years. Its solvency ranks better than 80% of 50 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.5% (low).
Checked score
Score 2025
86
/ 100
Excellent
The score weighs solvency, liquidity, profitability and financial development. Bankruptcy probability contributes 35%. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability77▲+4
Solvency98▲+1
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
0.5%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €35k at 30 days acceptable
Liquidity ample (current ratio 5.11 against 5.18 in 2024; short-term debt: 16.2% and cash: 32.4% of total assets), and 27.1% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
72.9%
Return on assets
6.6%
Age of the figures
15 mo
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Sector 21
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
neutral · Filed after the deadline
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 20-02-2026, 20 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
20 d late
2024
24 d early
2023
9 d late
2022
6 d early
2021
3 d early
2020
4 d early
2019
42 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
30-06-2026 close16-09-2026 today31-01-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€425k▲ 10.0%
2024 · €386k
2019: €31k
2020: €163k
2021: €354k
2022: €366k
2023: €369k
2024: €386k
2019 → 2025
Total assets
€582k▲ 8.6%
2024 · €536k
2019: €323k
2020: €564k
2021: €673k
2022: €600k
2023: €557k
2024: €536k
2019 → 2025
Net result
€38k▲ 117%
2024 · €18k
2019: €24k
2020: €132k
2021: €191k
2022: €12k
2023: €3k
2024: €18k
2019 → 2025
Working capital
€387k▲ 20.4%
2024 · €322k
2019: €-25k
2020: €113k
2021: €285k
2022: €268k
2023: €282k
2024: €322k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€354k-€366k▲ 3.5%€369k▲ 0.7%€386k▲ 4.8%€425k▲ 10.0%
Operating result€257k-€19k▼ 92.7%€6k▼ 69.8%€27k▲ 368%€54k▲ 103%
Net result€191k-€12k▼ 93.6%€3k▼ 79.1%€18k▲ 588%€38k▲ 117%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
After the dip in 2023 the operating result has climbed two years in a row; 2025 is 103% above 2024.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €582k
Fixed assets
€101k▼ 26.9%
Current assets
€482k▲ 20.8%
Equity and liabilities €582k
Equity
€425k▲ 10.0%
Debt
€158k▲ 5.0%
The debt ratio falls from 28.0% to 27.1%. Equity and debt are higher.
Key figures and ratios
EBITDA
€94k▲
2024 · €69k
Cash flow
€79k▲
2024 · €60k
Solvency
72.9%▲
2024 · 72.0%
Current ratio
5.11▼
2024 · 5.18
Quick ratio
2.62▼
2024 · 2.79
Debt / equity
0.37▼
2024 · 0.39
ROE
9.1%▲
2024 · 4.6%
ROA
6.6%▲
2024 · 3.3%
Interest coverage
38.25▲
2024 · 21.94
Debt
€158k▲
2024 · €150k
Debt ≤ 1 year
€94k▲
2024 · €77k
Debt > 1 year
€60k▼
2024 · €70k
Income taxes
€15k▲
2024 · €7k
Staff costs
€27k▼
2024 · €32k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€536k€582k▲
Fixed assets21/28€138k€101k▼
Intangible fixed assets21€17k€13k▼
Tangible fixed assets22/27€113k€80k▼
Plant, machinery and equipment23€91k€63k▼
Furniture and vehicles24€4k€2k▼
Other tangible fixed assets26€17k€15k▼
Financial fixed assets28€8k€8k=
Current assets29/58€399k€482k▲
Stocks and contracts in progress3€184k€235k▲
Stocks30/36€184k€235k▲
Amounts receivable within one year40/41€67k€49k▼
Trade receivables40€66k€49k▼
Other amounts receivable41€949-
Cash at bank and in hand54/58€142k€189k▲
Deferred charges and accrued income490/1€6k€10k▲
Equity and liabilities
Total equity and liabilities10/49€536k€582k▲
Equity10/15€386k€425k▲
Contributions10/11€100k€100k=
Profit (loss) carried forward14€286k€325k▲
Amounts payable17/49€150k€158k▲
Amounts payable after more than one year17€70k€60k▼
Financial debts170/4€70k€60k▼
Amounts payable within one year42/48€77k€94k▲
Current portion of amounts payable after more than one year42€14k€10k▼
Financial debts43-€3
Credit institutions430/8-€3
Trade debts44€28k€56k▲
Suppliers440/4€28k€56k▲
Taxes, remuneration and social security45€10k€9k▼
Taxes450/3€6k€5k▼
Remuneration and social security454/9€4k€4k▼
Other amounts payable47/48€24k€20k▼
Accrued charges and deferred income492/3€4k€3k▼
Income statement
Code20242025
Remuneration, social security and pensions62€32k€27k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€42k€40k▼
Other operating charges640/8€10k€8k▼
Gross operating margin9900€111k€129k▲
Operating profit (loss)9901€27k€54k▲
Financial income75/76B€2k€2k▲
Recurring financial income75€2k€2k▲
Financial charges65/66B€3k€2k▼
Recurring financial charges65€3k€2k▼
Profit (loss) for the period before taxes9903€25k€53k▲
Income taxes67/77€7k€15k▲
Profit (loss) for the period9904€18k€38k▲
Profit (loss) for the period to be appropriated9905€18k€38k▲
Appropriation of the result
Profit (loss) to be appropriated9906€286k€325k▲
Profit (loss) brought forward from the previous period14P€269k€286k▲
Social balance
Average headcount (FTE)90870.60.5▼
The notes to these accounts (11 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
20-02
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 20 days late
2025
07-01
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
09-02
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 9 days late
2023
30-06
Financial
Weakest financial yearnet €3k ▼79.1%
Net result drops to €3k, the lowest in the series; recovery starts the following year.
25-01
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
28-01
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
30-06
Financial
Highest result since 2019net €191k ▲44.7%
Operating result €257k, net result €191k, both a record.
30-06
Financial
Equity above €200kEq €354k ▲117%
3 profitable years in a row build equity to €354k.
27-01
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
30-06
Financial
Equity above €150kEq €163k ▲431%
2 profitable years in a row build equity to €163k.
2019
20-12
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
23-01
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2018
10-01
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
16-01
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
6 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Oudenaarde · 1 establishment unit since 2014
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Berchemweg 1399700 OudenaardeGround area
1.8 ha
Building footprint
3,994 m²
Volume, LiDAR
964 m³
2 parcels, Flanders · tallest building 5.7 m, ±1 floor. Linked by address, not a title deed.
1 establishment unit
D2S Pharma bv
since 20142.235.656.394
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 45508B0039/00E003 | Flanders | 1.5 ha | 1 · 3,743 m² | - |
| 45023A1403/00N002 | Flanders | 2,427 m² | 1 · 251 m² | 5.7 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1 · via establishment units: 1
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2023 · 1 entry · 126 EUR awarded · 126 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2023 | 1 | 126 EUR | 126 EUR |
Schemes
Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
Similar companies · same sector, comparable size
SOPACHEM
BE 0407.132.457
Zwevegem · Eq €427k
MERIDIAN BIOSCIENCE EUROPE
BE 0408.081.968
Braine-l'Alleud · Eq €455k
MY HEALTH INTERNATIONAL
BE 0684.959.659
Lummen · Eq €376k
PROMACON
BE 0444.408.963
Hove · Eq €374k
PHARMACIE DE GIVRY
BE 0897.812.697
Quévy · Eq €484k
Of 149 companies in sector 21100 we hold annual accounts for 108. 73 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded30-09-2014
Fiscal year end30-06
Activities, NACEBEL
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
20420Manufacture of chemicals and chemical products
46460Wholesale of pharmaceutical and medical goods
82990Other business support services
Sources
Crossroads Bank for EnterprisesNational Bank · 10 filingsAddress and cadastre registers
Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
1 entryE-mail:info@d2spharma.com